RadNet Inc focuses on imaging growth as investors track the stock
RadNet Inc operates a large network of outpatient diagnostic imaging centers across the U.S., offering services like MRI, CT, and mammography. The company's performance is tied to healthcare utilization, insurance reimbursement, and its strategy of scaling imaging footprint and optimizing operations. Growth drivers include aging populations and increased use of radiology, while risks involve reimbursement changes and regulatory oversight.
How RadNet’s (RDNT) AI Reporting Tools Could Improve Imaging Center Scale and Workflow
RadNet (RDNT) is positioned as a leading medical care facilities stock, with analysts projecting a 30.6% upside. A key development is the commercial launch of DeepHealth's Reporting Pro, an AI tool designed to enhance radiology reporting and workflow efficiencies. This technology push aims to make diagnostic imaging more scalable, moving RadNet beyond a traditional imaging operator towards a digital health solution provider.
RDNT's unit DeepHealth expands AI breast suite with FDA-cleared tools
DeepHealth, a unit of RadNet (RDNT), has received FDA clearance for its Saige-Dx (2.0) and Saige-Q software. These AI-powered tools are designed to enhance radiologists' ability to detect breast cancer and assess breast density, expanding DeepHealth's breast imaging suite.
If You Invested $1,000 in Radnet (RDNT)
This article analyzes the historical performance of a $1,000 investment in Radnet (RDNT) over 1, 5, and 10 years, showing significant returns, particularly for the 10-year period. It also provides annual returns for RDNT versus the S&P 500 and details about Radnet's business, including its diagnostic imaging centers and its AI-powered Digital Health segment, DeepHealth.
10 Best Medical Care Facilities Stocks to Buy According to Analysts
This article identifies RadNet, Inc. (NASDAQ:RDNT) as one of the top medical care facilities stocks, highlighting its focus on outpatient diagnostic facilities and recent technological advancements, such as the launch of Reporting Pro by its subsidiary DeepHealth. Analysts project a 30.6% average upside for RadNet. The company's push into digital health positions it as more than a traditional imaging operator, aiming to scale its care model.
Is RadNet’s (RDNT) Russell Index Exit Recasting Its AI-Driven Growth Story?
RadNet (RDNT) was removed from several Russell value benchmarks, including the Russell 3000, 2500, and 2000 Value indexes, which could impact its investor base and liquidity. This exclusion, combined with recent debt funding for AI expansion, prompts a re-evaluation of its AI-driven growth strategy and financial flexibility. Despite potential short-term trading effects, the core narrative revolves around scaling AI productivity against risks like reimbursement pressure and capital intensity.
RadNet Stock To $42?
RadNet (RDNT) stock has recently fallen by 19.3% in less than a month, from $75.22 to $60.68, and Trefis believes it could fall further, potentially reaching $42. Despite this, historical data suggests that sharp dips in RDNT stock (20% or more within 30 days) have led to a median 12-month return of 19% and a median peak return of 66%. The article also notes that RadNet passes basic financial quality checks regarding revenue growth, profitability, and cash flow.
RadNet Stock (-9.0%): Sell-off Continues on Acquisition, Cost Concerns
RadNet's stock experienced a significant 9.0% sell-off, driven by concerns related to a recent acquisition and rising costs. This downturn reflects investor apprehension regarding the company's financial outlook following these developments.
RDNT - Radnet Inc Options
This page provides comprehensive financial data and performance metrics for Radnet Inc (RDNT), including its last closing price, market capitalization, income, sales, and various valuation ratios. It also details insider and institutional ownership, profitability margins, and stock performance over different periods, alongside analyst recommendations. The article highlights key financial figures and market indicators relevant to investors.
RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared Tools
RadNet's subsidiary, DeepHealth, has received FDA clearance for two new AI-powered functionalities within its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior exam integration into ProFound Pro (marketed as Mammo Dx). These tools enhance early disease detection by assessing cardiovascular risk and comparing current and past mammograms for lesion changes, respectively. The company expects these additions to strengthen its competitive position and support its AI-driven growth strategy, with the breast imaging market projected to grow significantly.
RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared Tools
RadNet's subsidiary, DeepHealth, recently obtained FDA clearances for two new functionalities within its AI-powered Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior exam integration into ProFound Pro, marketed as Mammo Dx. These additions enhance early disease detection, provide comprehensive patient overviews for radiologists, and are commercially available in the U.S. This expansion strengthens DeepHealth's breast imaging platform, addressing both cancer detection and cardiovascular risk assessment.
Is RadNet (RDNT) Below Fair Value On Its Russell Index Removal?
RadNet (RDNT) has been removed from several Russell value indices, which may impact institutional trading. Despite a recent firming of its share price, the stock is still down 14.39% year-to-date, though it shows strong long-term returns. Simply Wall St's analysis suggests RadNet is about 32% undervalued with a fair value of $89.75, primarily due to its investments in AI-powered imaging solutions, although the sales-based valuation presents a more cautious outlook.
RadNet, Inc.(NasdaqGM: RDNT) dropped from Russell Small Cap Comp Value Benchmark
RadNet, Inc. (NasdaqGM: RDNT) has been dropped from the Russell Small Cap Comp Value Benchmark. The company, a national provider of fixed-site diagnostic imaging services, operates 435 outpatient imaging centers and also has a Digital Health segment focusing on AI solutions for radiology. This news follows several recent announcements, including FDA clearance for two of DeepHealth's AI breast imaging tools and a new $250 million incremental term loan for strategic growth.
Technical Reactions to RDNT Trends in Macro Strategies
This article analyzes Radnet Inc. (NASDAQ: RDNT) using AI models to provide technical reactions and trading strategies. Key findings indicate strong near and mid-term sentiment but a weak long-term outlook, with resistance being tested. The analysis offers specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies.
Price to earnings forward of RadNet, Inc. – NASDAQ:RDNT
The article focuses on the "Price to earnings forward" metric for RadNet, Inc. (NASDAQ: RDNT), a company in the Health Services sector described on TradingView. It appears to be a financial data page rather than a detailed news article, providing context within the TradingView platform for financial analysis.
Price to sales forward of RadNet, Inc. – NASDAQ:RDNT
This page provides information on the "Price to sales forward" metric for RadNet, Inc. (NASDAQ: RDNT). It mentions that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to be a stub or a section from a larger financial data platform.
Enterprise value to EBITDA forward of RadNet, Inc. – FWB:PQIA
This article provides the enterprise value to EBITDA forward for RadNet, Inc. (FWB:PQIA) as listed on the Frankfurt Stock Exchange. It indicates a specific period value and changes but does not offer further details. The content is primarily a listing with market data and copyright information from TradingView and its partners.
Enterprise value to revenue forward of RadNet, Inc. – NASDAQ:RDNT
This article focuses on the enterprise value to revenue forward metric for RadNet, Inc. (NASDAQ: RDNT). It appears to be a financial data snippet or a link to more detailed financial information for the company on the TradingView platform. The content is very brief, mainly serving as a heading for financial analysis of RadNet.
Enterprise value to EBIT forward of RadNet, Inc. – FWB:PQIA
This article provides a brief financial snippet for RadNet, Inc. (FWB:PQIA), specifically focusing on its enterprise value to EBIT forward metric. The content indicates the period, value, and change percentage for this financial ratio. The article is hosted on TradingView, a financial platform providing market data and analysis.
Does RadNet’s (RDNT) New Breast AI Suite Subtly Redefine Its Diagnostic Platform Strategy?
RadNet's subsidiary DeepHealth received FDA clearance for two new AI tools for its Breast Suite, including Breast Arterial Calcification Assessment and enhanced prior exam integration. These tools, now commercially available, aim to increase the clinical value of RadNet's breast imaging platform by combining cancer detection with cardiovascular risk insights. The adoption of these AI capabilities is crucial for RadNet to justify increased leverage for expansion and achieve its projected revenue and earnings growth.
RadNet, Inc. Actuals & Estimates (BMV:RDNT)
This article provides financial actuals and estimates for RadNet, Inc. (RDNT) on the Mexican Stock Exchange, including income statement, balance sheet, and cash flow data. It details stock performance, analyst forecasts ranging from 1,123.60 MXN to 1,728.61 MXN, and upcoming earnings dates. The piece also covers market capitalization, historical highs and lows, and key financial metrics like revenue, net income, and EBITDA.
PQIA Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for RadNet, Inc. (PQIA), based on analysis from 8 analysts. It details the maximum and minimum price estimates, past financial performance including earnings and revenue, and answers common questions about the stock, such as its ticker, all-time high/lows, earnings dates, dividends, and employee count. The overall sentiment appears to be an analytical overview for potential investors, including a warning to conduct personal research.
RadNet Inc (RDNT) Institutional Confidence
RadNet Inc (RDNT) has an institutional shareholding score of 10.00, placing it first among 76 companies in the Healthcare Providers & Services industry. Institutional shareholding increased by 12.32% quarter-over-quarter, with Steven Cohen being the largest institutional shareholder, holding 1.09% of outstanding shares. Major institutional holders include BlackRock, Kaminsky (Sandy Nyholm), RTW Investments, Beck, Mack & Oliver LLC, T. Rowe Price Associates, State Street, and Geode Capital Management.
RadNet Inc (RDNT) Stock Up 3.1% and Still Undervalued -- GF Score
RadNet Inc (RDNT) saw its stock rise by 3.1% to $60.04, and GuruFocus classifies it as modestly undervalued with a GF Value™ of $66.68. Despite the undervaluation and a strong GF Score™ of 79/100, concerns exist due to a low financial strength score of 4/10 and recent insider selling totaling $3.0 million, without any reported insider purchases. This suggests potential caution for investors, despite the stock's intrinsic value appeal.
RDNT Forecast — Price Target — Prediction for 2027
RadNet, Inc. (RDNT) has a current stock price of $60.01 and analysts have set a 1-year price target of $89.75, with estimates ranging from $65.00 to $100.00. The company's stock has shown positive growth recently, with a 1.70% increase in the last 24 hours and 10.46% over the previous week. RadNet is scheduled to release its next earnings report on August 11, 2026.
DeepHealth adds heart-risk screening to breast mammograms with FDA OK
DeepHealth, a subsidiary of RadNet, has received two FDA 510(k) clearances for its AI-powered Breast Suite: BAC Assessment and Mammo Dx. BAC Assessment identifies breast arterial calcifications, a potential indicator of cardiovascular disease, during standard mammograms, showcasing over 90% sensitivity and 88% specificity. Mammo Dx integrates prior exam data to improve cancer detection by enabling comparison of breast tissue changes over time, aiming to reduce false positives and unnecessary recalls.
DeepHealth Receives Two FDA Clearances Enabling it to Add
DeepHealth, a subsidiary of RadNet, has received two FDA 510(k) clearances for new functionalities within its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior exam integration into ProFound Pro (now Mammo Dx). These additions aim to enhance cancer detection rates, reduce recalls, and provide cardiovascular
DeepHealth receives FDA clearances for AI Mammo Dx breast suite
DeepHealth, a RadNet subsidiary, has secured two FDA 510(k) clearances for its AI-powered Mammo Dx Breast Suite. These clearances cover BAC Assessment for cardiovascular risk insights and prior exam integration, aiming to enhance breast cancer detection, reduce false positives, and support clinical decisions. The new features further expand RadNet's AI capabilities in diagnostic imaging for improved women's health and oncology outcomes.
DeepHealth Receives Two FDA Clearances Enabling it to Add
DeepHealth, a subsidiary of RadNet, has received two FDA 510(k) clearances for new functionalities in its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior exam integration into ProFound Pro (now Mammo Dx). These additions aim to enhance breast cancer detection, reduce recall rates, and provide cardiovascular insights from routine mammograms, offering radiologists a more comprehensive patient overview. The new tools are designed to improve early disease detection and are now commercially available in the U.S.
RadNet Inc (RDNT) Stock Up 3.8% and Still Undervalued -- GF Scor
RadNet Inc (RDNT) shares rose 3.8% to $55.74, and according to GuruFocus's GF Value™, the stock is considered 16.4% undervalued with an estimated fair value of $66.68. Despite a strong GF Score™ of 79/100, which suggests good long-term return potential, the company exhibits financial vulnerabilities with a strength rating of 4/10 and recent insider selling of $2.8 million. Its P/E ratio of 112.4x is also slightly above its 5-year median, raising questions about sustainable valuation.
RadNet (RDNT) director trims stake with 2,699-share open-market sale
RadNet, Inc. director David L. Swartz sold 2,699 shares of common stock at $53.89 per share in an open-market transaction. Following this sale, Swartz directly holds 177,013 shares, with an additional 37,019 shares indirectly held through his spouse. This transaction was reported via a Form 4 filing, providing transparency on insider trading activity at RadNet (RDNT).
RadNet, Inc. (RDNT) Stock Analysis: A 67% Potential Upside Beckons Investors Amid Healthcare Growth
RadNet, Inc. (RDNT) is a leading provider of outpatient diagnostic imaging services with a market cap of $4.23 billion. Despite its current stock price being near its 52-week low, analysts project a 67% potential upside with an average target price of $89.75, backed by unanimous "Buy" recommendations. The company's strategic focus on AI-powered health informatics and strong free cash flow position it for future growth in the healthcare technology sector.
RadNet Stock - analyst consensus and sector view on imaging group
This article examines RadNet stock (RDNT), a major operator of outpatient diagnostic imaging centers in the US, focusing on analyst consensus and its position within the diagnostic imaging sector. It highlights recent financial results, including a Q1 2024 revenue of $431 million, and notes positive analyst views despite continued investment in AI and network expansion. The piece also compares RadNet to peers and explains its revenue generation through MRI, CT, PET/CT, X-ray, ultrasound, and mammography services, alongside radiology-focused IT and AI solutions.
RadNet president & CEO Cornelis Wesdorp sells $276k in stock By Investing.com
RadNet's President and CEO of Digital Health, Cornelis Wesdorp, sold 4,750 shares of the company's stock for approximately $276,022. This transaction occurred as the stock trades near its 52-week low, although analysts expect RadNet to achieve profitability this year. The company recently secured a $250 million term loan and released an AI-powered radiology reporting solution.
RadNet president & CEO Cornelis Wesdorp sells $276k in stock
RadNet's President and CEO of Digital Health, Cornelis Wesdorp, sold 4,750 shares of company stock for approximately $276,022. This transaction occurred amidst a decline in RadNet's stock price and recent financial activities including an incremental term loan and positive analyst forecasts for future profitability. The company has also made advancements in AI-powered radiology reporting solutions.
RadNet president & CEO Cornelis Wesdorp sells $276k in stock
RadNet's President and CEO of Digital Health, Cornelis Wesdorp, sold 4,750 shares of the company's common stock for approximately $276,022 on June 16, 2026. This transaction occurred as the stock trades near its 52-week low. Despite the recent sale, analysts project RadNet to achieve profitability this year, and the company has recently secured significant term loans and introduced a new AI-powered radiology reporting solution.
RadNet (RDNT) digital health CEO sells 4,750 shares in open-market trade
RadNet, Inc.'s Pres & CEO of Digital Health, Cornelis Wesdorp, sold 4,750 shares of common stock at $58.11 per share in an open-market transaction. Following this sale, Wesdorp retains a significant equity position, directly owning 69,075 shares. This insider transaction was reported via a Form 4 filing and is categorized as a moderate impact with negative sentiment.
[144] RadNet, Inc. SEC Filing
This article details a Form 144 SEC filing by RadNet, Inc. (RDNT), indicating a proposed sale of 2,699 shares of common stock with an aggregate market value of $145,449.38. The shares were acquired on June 10, 2026, as restricted stock from the issuer and are intended to be sold on June 18, 2026, via Morgan Stanley Smith Barney LLC on NASDAQ. The filing includes standard disclosures and signatory representations.
Spouse of RadNet (RDNT) CEO gifts 90 shares to family trusts
RadNet, Inc. CEO Howard G. Berger reported that his spouse made a bona fide gift of 90 shares of RadNet common stock to family trusts, with a reported price of zero. This transaction is categorized as a routine, non-market transfer rather than an open-market purchase or sale. Following this gift, Berger directly holds 498,405 shares, and his spouse indirectly holds 19,910 shares attributed to him.
RadNet Inc (RDNT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of RadNet Inc (RDNT), noting its current valuation score of 9.68, ranking 8th in its industry. It highlights the company's P/E ratio of -306.22, while also indicating that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The report was updated on June 17, 2026, showing the stock trading at 53.740 USD.
Why RadNet (RDNT) Stock Is Down Today
RadNet (RDNT) stock fell 3.9% after its President and CEO of Eastern Operations, Stephen M. Forthuber, sold over $2.5 million worth of company stock. Large insider stock sales often lead to investor concern, signaling that the executive believes the stock might be fairly valued. RadNet's shares have been volatile, and the company is down 24.7% since the beginning of the year.
Trading the Move, Not the Narrative: (RDNT) Edition
This report from Stock Traders Daily provides an AI-driven analysis for Radnet Inc. (NASDAQ: RDNT), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies an exceptional 78.3:1 risk-reward setup, targeting a 23.1% gain versus a 0.3% risk, and outlines specific institutional trading strategies including position, momentum breakout, and risk hedging. The analysis includes multi-timeframe signal data with support and resistance levels.
Radnet’s Stephen Forthuber sells over $2.5m in company stock
Stephen M. Forthuber, President & CEO-Eastern Operations at RadNet, Inc. (NASDAQ:RDNT), sold over $2.5 million worth of company stock on June 15, 2026, disposing of 44,067 shares. Following these transactions, Forthuber still directly holds 507,199 shares. This insider sale occurs as RadNet also reported mixed Q1 2026 earnings and is actively pursuing significant loans for expansion and acquisitions.
Insider Sell: Stephen Forthuber Sells 44,067 Shares of RadNet In
Stephen Forthuber, President & CEO-Eastern Operations of RadNet Inc (RDNT), sold 44,067 shares of the company on June 15, 2026, reducing his total holdings to 507,199 shares. This transaction is part of a trend of 14 insider sells and no buys at RadNet Inc over the past year. The stock is currently trading at $58.16, making it modestly undervalued compared to its GF Value of $66.43.
Morgan Stanley reports RDNT resale items (NASDAQ: RDNT) in Form 144
Morgan Stanley Smith Barney LLC has filed a Form 144 detailing proposed resale of RadNet (RDNT) common stock. The filing indicates securities totaling 4,750 shares with a monetary figure of $269,372.50, and includes compensation-related entries for 2024 and 2025. This document provides notice of potential sales, but does not confirm that transactions have occurred.
RadNet (RDNT) Eastern Operations CEO Forthuber sells 44,067 shares in open market
RadNet, Inc.'s President and CEO of Eastern Operations, Stephen M. Forthuber, reported selling 44,067 shares of company common stock in two open-market transactions. The sales were executed at weighted average prices of approximately $58.61 and $57.79 per share, totaling over $2.5 million. Despite these sales, Forthuber retains a significant direct holding of over 500,000 RadNet shares, indicating a partial reduction rather than a full exit from his position.
How New AI Reporting Platform and Cheaper Debt at RadNet (RDNT) Have Changed Its Investment Story
RadNet recently secured a US$250 million term loan with lower interest rates and commercially launched Reporting Pro, an AI-powered radiology reporting platform. These developments highlight the company's commitment to technology-driven imaging services and growth through acquisitions, potentially influencing its investment narrative despite ongoing losses and rising debt. While the AI platform tests the possibility of improved utilization and margins, investors should be mindful of the increased debt obligations and interest coverage pressures.
How New AI Reporting Platform and Cheaper Debt at RadNet (RDNT) Have Changed Its Investment Story
RadNet, Inc. has secured a new US$250 million incremental term loan with lower interest rates and launched its AI-powered radiology reporting platform, Reporting Pro. These developments are viewed as supporting the company's growth through technology-driven imaging services and acquisition-fueled expansion. While these moves are expected to enhance efficiency and reinforce RadNet's AI strategy, investors are cautioned to consider the potential balance sheet pressure from increased debt obligations.
How New AI Reporting Platform and Cheaper Debt at RadNet (RDNT) Have Changed Its Investment Story
RadNet recently secured a US$250 million term loan with lower interest and launched Reporting Pro, an AI-powered radiology reporting platform. These developments bolster RadNet's strategy of technology-driven imaging services and acquisition-fueled expansion, with the AI platform expected to impact utilization and margins. While the new debt facilitates growth, investors should consider the implications of rising debt obligations on future profitability.
Q1 2026 RadNet Inc Earnings Call Transcript
RadNet Inc (RDNT) reported record first-quarter revenue and adjusted EBITDA for Q1 2026 despite severe weather, with revenue increasing by 22.1% and adjusted EBITDA by 36.3%. The company expanded its market presence through acquisitions and saw significant growth in its Digital Health segment's annual recurring revenue. However, challenges include integration of new acquisitions, potential impacts from Medicare reimbursement rates, and radiologist burnout.
